We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

64 hedge funds and large institutions have $117M invested in Gyre Therapeutics in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

637% more call options, than puts

Call options by funds: $2.31M | Put options by funds: $313K

17% more capital invested

Capital invested by funds: $100M → $117M (+$16.9M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less funds holding

Funds holding: 74 → 64 (-10)

14% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 21

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
64
Holders Change
-10
Holders Change %
-13.51%
% of All Funds
1.85%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
18
Reduced
21
Closed
17
Calls
$2.31M
Puts
$313K
Net Calls
+$1.99M
Net Calls Change
+$978K

Top Buyers

1
CCM
Camber Capital Management
Massachusetts
+$6.46M
2
Franklin Resources
Franklin Resources
California
+$5.21M
3
SCM
Sarissa Capital Management
Connecticut
+$1.55M
4
TC
TFS Capital
Pennsylvania
+$670K
5
AIA
Arbor Investment Advisors
North Carolina
+$489K

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.88M
2
SFM
Sphera Funds Management
Israel
-$1.25M
3
BC
Broadfin Capital
New York
-$1.24M
4
Goldman Sachs
Goldman Sachs
New York
-$1.05M
5
Millennium Management
Millennium Management
New York
-$992K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$29.3M – – –
NMC
2
NEA Management Company
Maryland
$21.7M – – –
Franklin Resources
3
Franklin Resources
California
$11.2M +$5.21M +1,408 +88%
CCM
4
Camber Capital Management
Massachusetts
$7.41M +$6.46M +1,746 +743%
BIT
5
BlackRock Institutional Trust
California
$6.33M -$874K -236 -12%
Vanguard Group
6
Vanguard Group
Pennsylvania
$4.76M +$400K +108 +9%
BFA
7
BlackRock Fund Advisors
California
$3.74M +$29.6K +8 +0.8%
Jennison Associates
8
Jennison Associates
New York
$3.32M +$11.1K +3 +0.3%
DM
9
Deerfield Management
New York
$2.93M – – –
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$2.73M +$222K +60 +9%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$2.55M -$81.4K -22 -3%
State Street
12
State Street
Massachusetts
$2.19M +$7.4K +2 +0.3%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$1.97M -$70.3K -19 -3%
Northern Trust
14
Northern Trust
Illinois
$1.68M -$167K -45 -9%
SCM
15
Sarissa Capital Management
Connecticut
$1.56M +$1.55M +418 New
TC
16
TFS Capital
Pennsylvania
$1.41M +$670K +181 +92%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$1.12M -$11.1K -3 -1%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$921K +$18.5K +5 +2%
Goldman Sachs
19
Goldman Sachs
New York
$837K -$1.05M -283 -56%
Deutsche Bank
20
Deutsche Bank
Germany
$767K -$14.8K -4 -2%
BCM
21
Bridgeway Capital Management
Texas
$681K +$163K +44 +32%
TCIM
22
TIAA CREF Investment Management
New York
$621K – – –
Two Sigma Advisers
23
Two Sigma Advisers
New York
$576K +$7.4K +2 +1%
Morgan Stanley
24
Morgan Stanley
New York
$546K +$211K +57 +64%
AIA
25
Arbor Investment Advisors
North Carolina
$495K +$489K +132 New
1
2 3 4

GYRE Hedge Fund Activity: Q1 2014 in Review

64 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2014, worth a combined $117M — up 17% from $100M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of GYRE and 8 opened new positions — a net loss of 9 holders — while 21 trimmed existing stakes and 18 added.

The largest buyer was Camber Capital Management, adding an estimated $6.46M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.88M sold.

  • 64 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2014, down from 74 in Q4 2013.
  • Funds reported $117M of Gyre Therapeutics stock for Q1 2014, up 17% quarter-over-quarter.
  • 8 funds opened new Gyre Therapeutics positions in Q1 2014 and 17 closed out, a net change of -9 holders.
  • The largest Gyre Therapeutics buyer in Q1 2014 was Camber Capital Management, an estimated $6.46M added.
  • The largest Gyre Therapeutics seller in Q1 2014 was Wellington Management Group, an estimated $3.88M sold.

Based on aggregated 13F filings for Q1 2014.